Botox® is not the only botulinum toxin (BT), just the most expensive

Potential $6 million savings if plans switch from Botox® to lower-cost BT therapies

March 21, 2020

Study shows the potential for more than $6 million savings if plans switch from high-cost Botox® to lower-cost BT therapies to treat certain neurologic conditions

Prime analyzed health care claims from 15 million commercially insured members and found 58,000 BT claims totaling more than $76 million in 2018 (Migraine treatments accounted for 60 percent of the Botox spend). Besides migraines, the BT drug class treats three movement disorders – cervical dystonia (CD), limb spasticity (LS) and blepharospasm (BS). Botox has the highest cost of four drugs in the BT class, and accounted for 93 percent of BT spend. Other drugs in the BT drug class (like Abobotulinumtoxin A and Incobotulinumtoxin A) are priced between one-quarter and one-third less than Botox.

Prime’s ability to study medical claims found that shifting treatments from Botox to the equally effective, lower cost BT therapies would save an estimated $6.3 million annually. Because BT is administered in the doctor’s office, the study evaluated and found the timing of doses was not different between the BT products. Therefore, the number of expected administration visits would not increase if switching to a different BT product.

Real-World Botulinum Toxin Utilization and Treatment Cost for Cervical Dystonia and Limb Spasticity among 15 Million Commercially Insured Members (Fall 2019)

Related news


July 16, 2024

LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast

In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts


July 12, 2024

August 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market


July 12, 2024

High-Cost Therapy Profile: July 2024

Detailed information about Afamitresgene autoleucel Intravenous (IV)